Want to see AU:ZNO full AI Analyst Report?
Zoono Group Limited (ZNO) AI Stock Analysis
Zoono Group Limited
(ASX:ZNO)
The score is driven primarily by very weak financial performance, including persistent losses and negative cash flow. Technical indicators remain unfavorable, and the negative P/E with no dividend provides limited valuation support.
Zoono Group Limited (ZNO) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 19.39M
- Dividend Yield
- ―
- Average Volume (3M)
- 87.50K
- Price to Earnings (P/E)
- -11.8
- Beta (1Y)
- 0.32
- Revenue Growth
- 28.77%
- EPS Growth
- 59.60%
- Country
- Australia
- Employees
- 2
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Household & Personal Products
Zoono Group Limited Business Overview & Revenue Model
Company Description
Zoono Group Limited, along with its associated entities, specializes in the innovation, development, and global distribution of a variety of antimicrobial solutions, catering to both the New Zealand market and international clientele. Their product l...
Zoono Group Limited Financial Statement Overview
Summary
Financial performance is very weak overall: persistent losses, negative operating and free cash flow, and substantial erosion of equity outweigh the recent revenue rebound and modest leverage. The score is set at the minimum permitted level.
Income Statement
38NegativeBalance Sheet
34NegativeCash Flow
27Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.49M | 1.49M | 1.16M | 960.30K | 3.07M | 8.13M |
| Gross Profit | 595.90K | 595.90K | -281.53K | -4.36M | -625.33K | 2.10M |
| EBITDA | -1.22M | -1.22M | -3.11M | -8.03M | -342.66K | -4.91M |
| Net Income | -1.61M | -1.59M | -3.64M | -8.30M | -321.97K | -10.28M |
Balance Sheet | ||||||
| Total Assets | 5.28M | 5.28M | 5.87M | 9.01M | 13.40M | 17.68M |
| Cash, Cash Equivalents and Short-Term Investments | 220.15K | 220.15K | 47.30K | 1.79M | 759.99K | 3.30M |
| Total Debt | 298.54K | 298.54K | 544.56K | 726.63K | 868.36K | 1.00M |
| Total Liabilities | 2.37M | 2.37M | 2.89M | 2.76M | 3.24M | 8.41M |
| Stockholders Equity | 2.91M | 2.91M | 2.97M | 6.24M | 10.16M | 10.00M |
Cash Flow | ||||||
| Free Cash Flow | -1.29M | -1.33M | -1.58M | -2.89M | -3.55M | -996.61K |
| Operating Cash Flow | -1.29M | -1.33M | -1.58M | -2.89M | -3.55M | -974.11K |
| Investing Cash Flow | -338 | -349 | 0 | -58.73K | -53.49K | -107.62K |
| Financing Cash Flow | 1.45M | 1.50M | -190.15K | 3.99M | 873.62K | -54.99K |
Zoono Group Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ZNO, the sentiment is Neutral. The current price of 0.05 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.05, and below the 200-day MA of 0.06, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 51.96 is Neutral, neither overbought nor oversold. The STOCH value of 100.94 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:ZNO.
Zoono Group Limited Peers Comparison
Overall Rating
AU:PTL41Neutral- AU:ZNO39Underperform
AU:EVE38Underperform
AU:MCP38Underperform
AU:SKN37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| AU:PTL | 41Neutral | AUD 3.92M | -1.09 | -43.04% | ― | -29.84% | 22.51% |
| AU:ZNO | 39Underperform | AUD 21.33M | -11.75 | -50.40% | ― | 28.77% | 59.60% |
| AU:EVE | 38Underperform | AUD 4.76M | -2.11 | -49.07% | ― | -33.53% | 42.98% |
| AU:MCP | 38Underperform | AUD 18.71M | -0.89 | -33.14% | ― | -14.87% | -35.60% |
| AU:SKN | 37Underperform | AUD 6.97M | -0.44 | -430.23% | ― | -50.64% | -72.00% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:ZNO | Zoono Group Limited | 0.05 | -0.00 | -4.08% | |
| AU:PTL | Pental Ltd. | 0.02 | -0.03 | -52.08% | |
| AU:MCP | Mcpherson'S Limited | 0.13 | -0.11 | -46.94% | |
| AU:EVE | EVE Health Group Limited | 0.01 | -0.02 | -56.67% | |
| AU:SKN | Skin Elements Limited | ― | ― | ― |
Zoono Group Limited Corporate Events
Zoono Group Launches Speculative Rights Issue to Raise $1.6m
Zoono Group Limited has launched a pro rata non-renounceable rights issue, offering eligible shareholders one new share for every ten held at an issue price of $0.039, aiming to raise about $1.61 million before costs. The offer, which the company fla...
Zoono Group Plans Non-Renounceable Pro Rata Share Issue
Zoono Group Limited is an ASX-listed company operating in the hygiene and antimicrobial products sector. It develops and markets sanitising and protective solutions, with its shares trading under the ticker ZNO, providing access to equity capital fro...
Zoono launches rights issue to bolster capital while maintaining board control
Zoono Group Limited, a New Zealand-headquartered biotech firm, specialises in long-lasting antimicrobial sprays, wipes and foams for skin, surfaces and mould remediation, based on its proprietary ‘ZOONO molecule’. Its products, positioned...
Zoono launches rights issue and placement to fund global product development
Zoono Group Limited has launched a pro-rata non-renounceable rights issue, offering one new share for every ten held at $0.039 per share to raise up to A$1.61 million before costs. The proceeds are earmarked for a shelf-life extension project in key...
Zoono boosts capital with share placement and cleansing notice
Zoono Group Limited has issued 6,410,256 new fully paid ordinary shares at $0.039 per share via a placement to an existing shareholder, bolstering its capital base. The company has lodged a cleansing notice to ensure the new shares can be freely trad...
Zoono Group Raises Fresh Capital via Single-Investor Share Placement
Zoono Group Limited has applied for quotation of new ordinary fully paid shares on the ASX, under its existing code ZNO. The company completed a placement to a single investor, issuing 6,410,256 shares dated October 23, 2026, as part of an additional...
Zoono Raises A$250,000 to Accelerate Food Shelf-Life Technology and Asian Expansion
Zoono Group Limited, a biotech firm specialising in durable antiviral and antibacterial products for consumer and industrial use, is expanding its reach in shelf-life extension technologies for global food producers and retailers. Its proprietary Zoo...
Zoono Group Options Lapse, Trimming Potential Share Dilution
Zoono Group Limited has reported the cessation of a tranche of listed options in its capital structure, specifically the ZNOAP options that were scheduled to expire on June 30, 2026. These options, exercisable at $0.35, formed part of the companyR...
Zoono expands global shelf-life trials and shipping-container coatings
Zoono Group reported continued progress in commercialising its shelf-life extension products during the quarter to 30 September 2026, highlighting broader trials with major retailers in the U.K. on strawberries and raspberries and preparing expansion...
Zoono Directors Reshuffle Shareholdings to Signal Confidence
Zoono Group Limited has disclosed a change in directors’ interests after Non-Executive Director Marc Braterman sold 782,022 shares via an off-market trade at $0.05 per share to fund a personal matter, while retaining rights to acquire up to 5,0...
Zoono lodges updated ASX corporate governance statement for FY26
Zoono Group Limited has lodged its updated corporate governance statement for the year ended 30 June 2026 and confirmed it is available on the company’s investor website. The statement, current as of 27 August 2026 and approved by the board, ou...
Zoono Narrows Annual Loss as Revenue Rises but Keeps Dividend on Hold
Zoono Group Limited reported a 37.9% increase in revenues from ordinary activities to NZ$1.72 million for the year ended 30 June 2026, while significantly narrowing its loss after tax. The loss attributable to owners fell by around half to NZ$1.84 mi...
Zoono posts strong FY27 start on shelf-life orders and online sales
Zoono Group Limited has reported a strong start to its FY27 financial year, driven by continuing shelf-life extension orders that delivered unaudited July sales of about NZ$625,000 and an unaudited profit of NZ$110,000. The company also noted improve...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026